Abstract
The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Current Topics in Medicinal Chemistry
Title:A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology
Volume: 12 Issue: 15
Author(s): C. Faivre, D. Barbolosi and A. Iliadis
Affiliation:
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Abstract: The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Export Options
About this article
Cite this article as:
Faivre C., Barbolosi D. and Iliadis A., A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531469
DOI https://dx.doi.org/10.2174/156802612803531469 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Antibody Based Therapies in Acute Leukemia
Current Drug Targets Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Probiotics and Oral Health
Current Pharmaceutical Design Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry γ δ T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies
Current Molecular Medicine Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Role of Deoxyribonucleoside Kinases and Deoxyribonucleotide Pool Alterations in Nucleoside Reverse Transcriptase Inhibitor Induced Mitochondrial Toxicity
Current Medicinal Chemistry - Anti-Infective Agents Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry On the Cellular and Molecular Regulatory Transcriptional Mechanisms and Responsive Putative Pathways to Inflammatory Oxidative Stress Revisited: Current Immunological Breakthroughs and Views at a Glance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times
Recent Patents on Biotechnology Meet the Editorial Board Members
Current HIV Research Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued)